

Technosphere[®] Insulin (AFREZZA[®]) Publications

Potocka E, Baughman RA, Derendorf H. Population Pharmacokinetic Model of Human Insulin Following Different Routes of Administration. *J Clin Pharmacol*. 2010 [Epub ahead of print]

Marino MT, Cassidy JR, Baughman RA, et. al. A new c-peptide correction model used to assess bioavailability of regular human insulin *Biopharmaceuticals & Drug Disposition* 2010; 31: 428-435.

Marino MT, Costello D, Baughman R, et. al. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): Proof of concept studies in healthy normal volunteers and in patients with type 2 diabetes. *Clinical Pharmacology & Therapeutics* 2010; 88 (2): 243-250.

Potocka E, Amin N, Cassidy J, et. al Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease *Current Medical Research & Opinion* 2010: 28 (10): 2247-2253.:

Potocka E, Cassidy JP, Haworth P, et. al. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine *Journal of Diabetes Science and Technology* 2010: 4 (5): 1364-1173.

Rosenstock J, Lorger DL, Gnudi L, et. al. Prandial inhaled insulin plus basal insulin glargine versus twice daily bipart insulin for type 2 diabetes: a multicentre randomized trial *Lancet* 2010; 375: 2244-2253.

Rubin RR, Peyrot M. Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: The inhaled insulin treatment questionnaire (INTQ) *Health & Quality of Life Outcomes* 2010; 8: 32-40.

Peyrot M, Rubin RR. Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction. *Diabetes Technology & Therapeutics* 2010; 12:49-55.

Smutney CC, Friedman EM, Polidoro JM, et. al. Inspiratory efforts achieved in use of the Technosphere insulin inhalation system. *Journal of Diabetes Science and Technology* 2009; 3(5): 1175-1189.

Leone-Bay A, Grant M, Greene S, et. al. Evaluation of novel particles as an inhalation system for GLP-1. *Diabetes, Obesity and Metabolism* 2009; 11:1080-1089.

Kraft KS, Grant M. Preparation of macromolecule-containing drug powders for pulmonary delivery *Methods in Molecular Biology* 2009; 480: 165-174.

Angelo R, Rousseau K, Grant M, et. al. Technosphere[®] insulin: Defining the role of Technosphere particles at the cellular level *Journal of Diabetes Science and Technology* 2009;3: 545-554.

Rave K, Potocka E, Boss AH, et. Al. Pharmacokinetics and linear exposure of AFRESA[™] compared with the subcutaneous injection of regular human insulin *Diabetes, Obesity and Metabolism* 2009; 11:715:720.

Rosenstock J, Bergenstal R, DeFronzo RA, et. al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. *Diabetes Care* 2008; 31: 2177-2182..

Boss AH, Yu W, Ellerman K. Prandial insulin: Is inhaled enough? *Drug Development Research* 2008; 69:138-142.

Kaur N, Zhou B, Breitbeil F, et. al. A delineation of diketopiperazine self-assembly processes : Understanding the molecular events involved in Nε-(Fumaroyl)diketopiperazine of L-Lys (FDKP) interactions. *Molecular Pharmaceutics* 2008; 5: 294-315.

Rave K, Heise T, Heinemann L, et. Al. Inhaled Technosphere[®] Insulin in comparison to subcutaneous regular human insulin: Time action profile and variability in subjects with type 2 diabetes. *Journal of Diabetes Science and Technology* 2008; 2:205:212.

Tack CJ, Christov V, deGalan BE, et. al. Randomized forced titration to different doses of Technosphere[®] insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. *J Diabetes Sci Technol* 2008; 2:47-57.

Rave K, Pfuetzner A, Heise T, et. al. Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes, *Diabetes Care* 2007; 30: 2307-2308.

Richardson PC and Boss AH. Technosphere[®] Insulin technology. *Diabetes Technology & Therapeutics* 2007; 9: S65-S72.